Karyopharm Therapeutics, Inc. (KPTI)
1.79
+0.02
(+1.13%)
USD |
NASDAQ |
Sep 04, 16:00
1.79
0.00 (0.00%)
After-Hours: 20:00
Karyopharm Therapeutics Research and Development Expense (Quarterly) : 28.96M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 28.96M |
| March 31, 2026 | 33.78M |
| December 31, 2025 | 27.65M |
| September 30, 2025 | 30.42M |
| June 30, 2025 | 32.71M |
| March 31, 2025 | 34.54M |
| December 31, 2024 | 33.22M |
| September 30, 2024 | 36.05M |
| June 30, 2024 | 38.28M |
| March 31, 2024 | 35.34M |
| December 31, 2023 | 39.30M |
| September 30, 2023 | 35.47M |
| June 30, 2023 | 31.39M |
| March 31, 2023 | 32.05M |
| December 31, 2022 | 30.82M |
| September 30, 2022 | 31.18M |
| June 30, 2022 | 44.16M |
| March 31, 2022 | 41.88M |
| December 31, 2021 | 43.86M |
| September 30, 2021 | 38.27M |
| June 30, 2021 | 33.75M |
| March 31, 2021 | 36.82M |
| December 31, 2020 | 36.93M |
| September 30, 2020 | 36.80M |
| June 30, 2020 | 42.36M |
| Date | Value |
|---|---|
| March 31, 2020 | 33.76M |
| December 31, 2019 | 31.34M |
| September 30, 2019 | 26.27M |
| June 30, 2019 | 26.52M |
| March 31, 2019 | 37.97M |
| December 31, 2018 | 38.89M |
| September 30, 2018 | 36.43M |
| June 30, 2018 | 44.73M |
| March 31, 2018 | 41.32M |
| December 31, 2017 | 34.83M |
| September 30, 2017 | 25.24M |
| June 30, 2017 | 23.12M |
| March 31, 2017 | 24.08M |
| December 31, 2016 | 20.67M |
| September 30, 2016 | 19.89M |
| June 30, 2016 | 24.58M |
| March 31, 2016 | 21.80M |
| December 31, 2015 | 24.06M |
| September 30, 2015 | 25.92M |
| June 30, 2015 | 27.01M |
| March 31, 2015 | 20.75M |
| December 31, 2014 | 20.04M |
| September 30, 2014 | 15.95M |
| June 30, 2014 | 13.16M |
| March 31, 2014 | 10.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals, Inc. | 90.80M |
| Relay Therapeutics, Inc. | 76.48M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |